How is Adrenocortical Cancer being Managed in the UK?
Authors:
- 1 September 2009
- journal article
- research article
- Published by Royal College of Surgeons of England in The Annals of The Royal College of Surgeons of England
- Vol. 91 (6) , 489-493
Abstract
INTRODUCTION Adrenocortical carcinomas are rare. This case series is reported to give an overview of how adrenocortical carcinoma is currently managed in the UK. PATIENTS AND METHODS A retrospective review was made of case notes from patients with adrenocortical carcinomas presenting to the authors (TWJL, RDB, BJH, and DS-C) over the past 10 years in Newcastle, Sheffield and Cardiff. RESULTS Newcastle treated twelve, Sheffield eleven and Cardiff seven cases. The median follow-up was 25.5 months (range, 1–102 months). All tumours were greater than 5 cm in diameter. The majority presented with symptoms of hormone excess. Adrenalectomy was performed in 83% – this was radical in 30% and followed by excision of recurrence in 13%. Adjuvant mitotane was given in 64% of patients, in combination with cytotoxic chemotherapy in 20%. One-third of patients did not receive any adjuvant therapy. There was no significant difference in survival between the three centres. The majority of patients (57%) died during the period of follow-up of this study. The median survival was 37 months (range, 2–102 months). CONCLUSIONS The size of tumour, stage and mode of presentation, age and overall survival of patients in this study are comparable to published series of adrenocortical carcinomas from major endocrine surgical centres world-wide. Despite controversies about benefits, adjuvant mitotane was used in the majority of cases, whereas cytotoxic chemotherapy was only used in the minority. The exact role of adjuvant therapy in the management of adrenocortical carcinoma is not as well established as for other more common malignancies. Establishing a database for adrenocortical carcinomas in the UK would contribute to our understanding of the management of this disease.Keywords
This publication has 24 references indexed in Scilit:
- 18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in 13 consecutive patientsEuropean Journal of Endocrinology, 2004
- Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumorsEuropean Journal of Endocrinology, 2004
- Management of adrenocortical carcinomaClinical Endocrinology, 2003
- Clinical and molecular aspects of adrenocortical tumourigenesisAnz Journal of Surgery, 2003
- Results of Laparoscopic Adrenalectomy for Large and Potentially Malignant TumorsWorld Journal of Surgery, 2002
- Adrenocortical carcinomaCancer, 2001
- Adrenocortical carcinomas: surgical trends and results of a 253‐patient series from the French Association of Endocrine Surgeons study groupWorld Journal of Surgery, 2001
- Adrenal cortical carcinomaWorld Journal of Surgery, 2001
- Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumorsUrology, 2001
- SEVERE ADRENAL CORTICAL ATROPHY (CYTOTOXIC) AND HEPATIC DAMAGE PRODUCED IN DOGS BY FEEDING 2,2-BIS(PARACHLOROPHENYL)-1,1-DICHLOROETHANE (DDD OR TDE)1949